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Background: Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models
and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of
3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission
tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.
Methods: In vivo uptake of [18F]FLT and [18F]FDG in human ovary cancer xenografts in mice (A2780) were studied
after treatment with belinostat. Mice were divided in 2 groups receiving either belinostat (40 mg/kg ip twice daily
Day 0–4 and 6–10) or vehicle. Baseline [18F]FLT or [18F]FDG scans were made before treatment (Day 0) and
repeated at Day 3, 6 and 10. Tracer uptake was quantified using small animal PET/CT.
Results: Tumors in the belinostat group had volumes that were 462 ± 62% (640 mm3) at Day 10 relative to baseline
which was significantly different (P = 0.011) from the control group 769 ± 74% (926 mm3). [18F]FLT SUVmax
increased from baseline to Day 10 (+30 ± 9%; P = 0.048) in the control group. No increase was observed in the
treatment group. [18F]FDG SUVmean was significantly different in the treatment group compared to the control
group (P = 0.0023) at Day 10. Within treatment groups [18F]FDG uptake and to a lesser extent [18F]FLT uptake at
Day 3 were significantly correlated with tumor growth at Day 10.
Conclusions: [18F]FDG uptake early following treatment initiation predicted tumor sizes at Day 10, suggesting that
[18F]FDG may be a valuable biomarker for non-invasive assessment of anti-tumor activity of belinostat.
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During development of new anti-cancer drugs methods
to discriminate between effective and non-effective com-
pounds and, on an individual patient basis, between re-
sponders and non-responders are of wide interests. For
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distribution, and reproduction in any mediumThe non-invasive imaging modality positron emission
tomography (PET) assesses biological processes in intact
living tissue. The tracer 3’-deoxy-3’-[18F]fluorothymidine
([18F]FLT) is a thymidine analogue that is used to
image cell proliferation in vivo by PET, by measuring the
activity of thymidine kinase 1 (TK1) which is up-
regulated in the S-phase of cell cycle [1-6]. Pre-clinical
studies have evaluated tumor cell proliferation by use of
[18F]FLT PET after treatment with several different anti-
cancer agents in different tumor models. The results are
variable, ranging from a good correlation between early
changes in [18F]FLT tumor uptake and tumor responseentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tumor response [7-17]. The FLT tracer has been vali-
dated against the proliferation marker Ki67 in several
tumor types [18-20]. Ki67 protein measurements by im-
munohistochemistry are currently considered the gold
standard for measurement of cell proliferation in tumor
tissue specimens.
The tracer 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]
FDG) is today the most widely used PET tracer for
detecting and characterizing cancers. Changes in [18F]
FDG uptake following anti-cancer treatment have been
analyzed in several clinical studies; however, with vari-
able results [21,22]. The Response Evaluation Criteria In
Solid Tumors (RECIST) is a common method to assess
tumor response by use of anatomical imaging techniques
as computed tomography (CT) and magnetic resonance
imaging (MRI) [23,24]. One disadvantage of using the
tumor size as a response criterion for treatment is the
amount of time it requires before a volume response be-
comes evident. Therefore new biological measurements
are studied, and new guidelines have been suggested
using e.g. [18F]FDG PET for measurement of treatment
effect [25].
Belinostat (PXD101) is a histone deacetylase (HDAC)
inhibitor, a relatively new class of anti-cancer drugs
inhibiting the enzymes that deacetylate histone proteins.
Histone acetylation is on the epigenetic level involved in
regulation of gene expression. Belinostat induces anti-
cancer activity in part by enhancing histone acetylation
in tumor cells which causes alterations in gene expres-
sion [26-28]. However, the exact mechanism of how the
aberrant gene expression causes anti-tumor activity re-
mains unknown. Belinostat inhibits growth of human
ovarian cancer cell lines in vitro and belinostat has anti-
tumor activity in vivo in human A2780 ovarian cancer
xenografts in mice [26,27]. The anti-tumor activity of
belinostat is both related to inhibition of cell prolifera-
tion and induction of apoptosis and in several human
cancer cell lines belinostat has been shown to cause cell
cycle arrest in the G2/M phase [29-31]. We therefore
speculated that belinostat treatment would reduce up-
take of the cell proliferation tracer [18F]FLT.
Ovarian cancer is the most lethal of the gynecological
cancers in women, and although many patients show an
initial response to chemotherapy, numerous patients re-
lapse with drug-resistant metastases [32]. Belinostat has
both been tested as monotherapy and in combination
with different chemotherapeutics in various clinical trials
including trials containing ovarian cancer patients [33-39].
However, biomarkers for assessing tumor sensitivity and
stratifying patients into responders and non-responders to
HDAC inhibitors are currently lacking [40].
The aim of this study was to investigate if [18F]FLT
and [18F]FDG PET can be used as non-invasive imagingbiomarkers for monitoring of belinostat treatment. To
do so, we analyzed [18F]FLT and [18F]FDG uptake in a
human ovary cancer mouse model before and during
treatment with belinostat. Tracer uptake was compared




Animal care and all experimental procedures were
performed under the approval of the Danish Animal
Welfare Council (2006/561-1124). Female NMRI (Naval
Medical Research Institute) nude mice (8 weeks old)
were acquired from Taconic Europe (Lille Skensved,
Denmark) and allowed to acclimatize for one week in
the animal facility before any intervention was initiated.
The human ovarian carcinoma cell line A2780 (a gift
from R. Ozols, Fox Chase Cancer Center Philadelphia,
PA, January 2004) was used. For establishment of xeno-
grafts, 107 cells in 100 μL medium mixed with 100 μL
Matrixgel™ Basement Membrane Matrix (BD Biosci-
ences, San Jose, CA, USA) were injected subcutaneously
into the left and right flank respectively during
anesthesia with 1:1 v/v mixture of HypnormW (Janssen
Pharmaceutica, Beerse, Belgium) and DormicumW
(Roche, Basel, Switzerland). The cell line was tested free
of mycoplasma. A2780 was cultured in RPMI (Roswell
Park Memorial Institute) medium 1640 + GlutaMAX
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (Biological Industries, Israel) and 1%
penicillin-streptomycin (Invitrogen) in 5% CO2 at 37°C.
Synthesis of [18F]FLT and [18F]FDG
[18F]FLT was synthesized using 3-N-Boc-1-[5-O-(4,4'-
dimethoxytrityl)-3-O-nosyl-2-deoxy-β-D-lyxofuranosyl]thy-
mine as precursor on a GE TracerLab MX Synthesizer as
previously described [41]. All reagents and [18F]FLT
cassettes were purchased from ABX (Radeberg, Germany).
[18F]FDG was acquired from daily productions at
Rigshospitalet (Copenhagen, Denmark).
Experimental design
In vivo uptake of [18F]FLT and [18F]FDG in human
ovary cancer xenografts in mice (A2780) was studied at
various time points after treatment initiation. When
tumor volumes were approximately 100 mm3 mice were di-
vided in 2 groups receiving either belinostat (40 mg/kg ip)
or vehicle (L-arginine 80 mg/kg in isotonic sterile saline)
twice daily Day 0–4 and Day 6–10. Baseline [18F]FLT
or [18F]FDG PET scans were made before treatment
and repeated at Day 3, 6 and 10 after treatment initi-
ation. Tumor volume was followed by CT during the
experiments [42]. Tumor volumes were calculated
relative to volume at baseline. At Day 10 tumors were
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were analyzed by qPCR.
microPET and microCT imaging
The mice were injected i.v. with 9.5 ± 0.2 (mean ± SD) MBq
[18F]FLT or 10.0 ± 0.3 (mean ± SD) MBq [18F]FDG. Mice
were fasted overnight before each [18F]FDG PET scan [43].
One hour after tracer injection mice were anaesthetized
with 3% sevofluran (Abbott Scandinavia AB, Solna, Sweden)
mixed with 35% O2 in N2 and fixed on a bed in presence of
three fiducial markers allowing fusion of PET and CT
pictures. A PET scan was acquired using a MicroPET Focus
120 (Siemens Medical Solutions, Malvern, PA, USA)
followed by a microCT scan acquired with a MicroCATW II
system (Siemens Medical Solutions) as previously described
[41]. PET data were arranged into sinograms and subse-
quently reconstructed with the maximum a posteriori
(MAP) reconstruction algorithm. The pixel size was
0.866 × 0.866 × 0.796 mm and in the center field of view
the resolution was 1.2 mm full-width-at-half-maximum.
PET and microCT images were fused in the Inveon
software (Siemens Medical Solutions). Before fusion re-
gion of interests (ROIs) were drawn on the CT pictures
manually by qualitative assessment covering the whole
tumors and subsequently tumor volume and tracer up-
take, assessed by standard uptake value (SUV) was gen-
erated by summation of voxels within the tomographic
planes. SUV was calculated according to the formula
(CT*W)/Dinj, where CT is tissue radioactivity concentra-
tion, W is weight of the animal and Dinj is injected dose.
SUVmean was calculated from the mean radioactivity
concentration and SUVmax was calculated from the
voxel with the highest tracer concentration.
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was isolated from the biopsies with TRI
reagentW following the manufacturer’s instructions
(Molecular Research Center Inc., OH, USA). The concen-
tration of the RNA was determined by NanoDrop 1000
(Thermo Fisher Scientific, Wilmington, DE, USA). Total
RNA (0.3 μg) was reversed transcribed using the
Affinityscript™ QPCR cDNA Synthesis kit (Stratagene, La
Jolla, CA, USA) according to the manufacturer’s instruc-
tions. Samples were cooled down and stored at −20°C
until further use.
Primers were designed using Beacon Designer (PREMIER
Biosoft, Palo Alto, CA, USA). Primer sequences were
Ki67-FP: 5’-tcccgcctgttttctttctgac-3’, Ki67-RP: 5’-ctctcc
aaggatgatgatgctttac-3’, TK1-FP: 5’-gccgatgttctcaggaaaaa
gc-3’, TK1-RP: 5’-gcgagtgtctttggcatacttg-3’, GLUT1-FP:
5’-catcatcttcatcccggc-3’, GLUT1-RP: 5’-ctcctcgttgcggtt
gat-3’, GUSB-FP: 5’-tgagcaagactgatacca-3’, GUSB-RP:
5’-gctagaatagatgaccacaa-3’, HPRT-FP: 5’-caaagcctaagatg
agagt-3’, HPRT-RP: 5’-gccacagaactagaacat-3’. For eachgene the optimal primer concentration was found. All
assays were optimized to have efficiencies between 95%
and 105%. All samples were run in triplicate using one μl of
cDNA. To each sample a no-reverse transcription control
(NoRT) was included, and on each plate a no-template
control (NTC) was included.
Gene expression was quantified on a Mx3000PW real-
time PCR system from Stratagene. All gene of interests
(GOIs) and reference genes were quantified with BrilliantW
SYBRW Green QPCR Master Mix (Stratagene). The follow-
ing thermal profile was used in all experiments: 10 minutes
of denaturation at 95°C followed by 45 cycles of 30 seconds
denaturation at 95°C, 1 minute of annealing at 60°C and
1 minute extension at 72°C. A dissociation curve was
afterward acquired by denaturation of the products for
1 minute at 95°C followed by a stepwise increase in
temperature from 55°C to 95°C with steps of 0.5°C/cycle
where the duration of each cycle was 18 seconds.
QPCR data were analyzed in the qBase program. The
relative quantification of the GOIs was calculated using
two reference genes [44]. Data are presented as fold
changes in the treatment compared to the control group at
Day 10. The level of the GOIs was normalized to the geo-
metric mean of two reference genes. The two most stable
reference genes were found from a panel of 12 candidates
in the human reference gene panel (TATAA Biocenter AB,
Göteborg, Sweden) by use of the geNorm algorithm.
Statistical analysis
Comparison between the treatment and control group
was calculated using unpaired student’s t-test. Paired t-test
was used for intra-group comparisons. Bonferroni correc-
tion of P-values for multiple comparisons was applied.
Correlations between SUVmean or SUVmax and tumor
growth were calculated using linear regression. Calcula-
tions were made in PASW 18.0 (IBM Corporation,
Armonk, New York, USA). Data are reported as mean ±




Tumors in the control group had volumes that were
419 ± 39% at Day 6 and 769 ± 74% at Day 10 relative to
baseline. In the belinostat group tumors were 282 ± 30%
at Day 6 and 462 ± 62% at Day 10 relative to baseline
which were significantly less than the control group both
at Day 6 (p = 0.029) and Day 10 (p = 0.011) (Figure 1). At
baseline the tumor sizes in the treatment (130 ± 23 mm3)
and control group (118 ± 19 mm3) were identical.
[18F]FDG and [18F]FLT microPET imaging
When studied in treatment groups, no differences in
[18F]FLT uptake between treatment and control groups
Figure 1 Effect of belinostat on the growth of A2780 xenografts.
Tumor volume was determined by microCT. The mice were treated
with belinostat (40 mg/kg ip twice daily Day 0–4 and 6–10) or
vehicle. N = 12-13 tumors/group. *) p < 0.05 treatment versus control
group at same time point.
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SUVmax. [18F]FLT SUVmax uptake increased from
baseline to Day 10 (+30 ± 9%; p = 0.048) in the control
group. No increase in [18F]FLT SUVmax was observed
in the treatment group at Day 10 (Figures 2, 3).Figure 2 Tumor uptake of [18F]FLT and [18F]FDG following treatment wi
treated with either belinostat (40 mg/kg ip twice daily Day 0–4 and 6–10) or
[18F]FDG at baseline and Day 3, Day 6 and Day 10 after treatment start . [18F
SUVmax relative to baseline (left panel) and SUVmean relative to baseline (rig
versus baseline in same treatment group. #) p < 0.05, ##) p < 0.01, ###) p < 0.0[18F]FDG SUVmax was increased at Day 10 compared
to baseline in both the control (+95 ± 22%; p = 0.035) and
treatment group (+52 ± 8%; p = 0.0015). No significant
difference in SUVmax between treatment and control
group was observed at any time point. [18F]FDG
SUVmean was significant different in the treatment
compared to the control group (p = 0.0023) at Day 10.
Compared to baseline, [18F]FDG SUVmean uptake was
increased at Day 6 (+47 ± 8%; p = 0.013) and Day 10
(+75 ± 7%; p = 0.0013) in the control group. Compared
to baseline, [18F]FDG SUVmean uptake was increased
at Day 10 (+40 ± 4%; p < 0.001) in the treatment group
(Figures 2, 3). Within treatment groups [18F]FLT
SUVmean Day 3 was significantly correlated with rela-
tive tumor volume Day 10/baseline in the belinostat
group (r2 = 0.67; p = 0.02). [18F]FLT SUVmean Day 6
was correlated with tumor growth Day 10/baseline in
the belinostat group (r2 = 0.51; p = 0.07) however not
significant (Figure 4).
Within treatment groups [18F]FDG SUVmean Day 3
was correlated with tumor growth Day 10/baseline in
the belinostat group (r2 = 0.54; p = 0.06), however notth belinostat. Mice with human ovary cancer xenograft tumors were
vehicle and they were subjected to PET imaging with either [18F]FLT or
]FLT (upper panel) and [18F]FDG (lower panel) uptake measured as
ht panel). N = 5-7 tumors/group. *) p < 0.05, **) p < 0.01, ***) p < 0.001
01 treatment versus control group at same time point.
Figure 3 PET/CT images. Representative combined PET/CT images of [18F]FLT scans (upper panel) and [18F]FDG scans (lower panel) of mice
treated with belinostat (40 mg/kg ip twice daily Day 0–4 and 6–10) or vehicle respectively. Tracer uptake was measured in the same animals at
baseline, Day 3, Day 6 and Day 10. Dotted circles indicate the tumors.
Figure 4 Correlations between tumor uptake of [18F]FLT and tumor growth. Tumor growth was measured as tumor volume ratio Day 10/baseline.
The graphs show tumor growth correlated with uptake of [18F]FLT SUVmean and SUVmax at Day 3 and Day 6 respectively.
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Figure 6 Ki67, TK1 and GLUT1 gene expression. At Day 10 after
treatment start all tumors were excised and total RNA was isolated
and revers transcribed to cDNA. Expression of Ki67, TK1 and GLUT1
were measured with qPCR and normalized to the geometric mean
of two reference genes. Data are presents as fold changes in the
treatment compared to the control group at Day 10. N = 5-7
tumors/group. *) p < 0.05, **) p < 0.01, ***) p < 0.001 treatment
versus control group at same time point.
Jensen et al. BMC Cancer 2013, 13:168 Page 6 of 9
http://www.biomedcentral.com/1471-2407/13/168significant. [18F]FDG SUVmean Day 6 was signifi-
cantly correlated with tumor growth Day 10/baseline
(r2 = 0.68; p = 0.02). [18F]FDG SUVmax Day 3 was sig-
nificantly correlated with tumor growth Day10/baseline
(r2 = 0.70; p = 0.02) as were [18F]FDG SUVmax Day 6
(r2 = 0.83; p = 0.004) (Figure 5).
Ki67, TK1 and GLUT1 gene expression
The two most stable reference genes were beta-glucuronidase
(GUSB) and hypoxanthine phosphoribosyltransferase
1 (HPRT). The levels of Ki67, TK1 and GLUT1 were
normalized to the geometric mean of these two reference
genes. The gene expression was measured at Day 10 in the
treatment relative to the control group. Ki67 gene expres-
sion was unchanged in the treatment compared to the
control group at Day 10. TK1 gene expression was higher
in the treatment compared to the control group at Day
10 (1.40 ± 0.09 vs 1.00 ± 0.07; p = 0.006). GLUT1 gene
expression was lower in the treatment group compared to
the control group at Day 10 (0.65 ± 0.06 vs 1.00 ± 0.16;
p = 0.05) (Figure 6).
Discussion
In this study we found that [18F]FDG uptake following
initiation of treatment with the HDAC inhibitor
belinostat predicted tumor sizes at the end of treatment
in a mouse model of human ovary cancer. We observed
minor effects on [18F]FLT uptake following treatment
with belinostat. In a previous study lower tumor uptake
of [18F]FLT was observed following treatment with the
HDAC inhibitor LAQ824 in a human colon carcinoma
mouse model [11]. LAQ824 is, like belinostat, aFigure 5 Correlations between tumor uptake of [18F]FDG and tumor grow
The graphs show tumor growth correlated with uptake of [18F]FDG SUVmeanhydroxamate HDAC inhibitor [45]. However, despite
belonging to the same class of HDAC inhibitors, we
did not find the same change in [18F]FLT uptake
following treatment initiation with belinostat. The
changes in [18F]FLT uptake was followed by a reduction in
TK1 transcription and translation in the study with
LAQ824 [11]. Interestingly, we observed an increase in
TK1 gene expression following treatment with belinostat. It
has been shown in a colon cancer cell line, that treatment
with belinostat reduces the levels of thymidylate synthase
(TS) [28]. An effect of TS inhibition can be up-regulation
of the salvage nucleotide pathway leading to increased
uptake of thymidine and hence [18F]FLT [8,46,47]. Thisth. Tumor growth was measured as tumor volume ratio Day 10/baseline.
and SUVmax at Day 3 and Day 6 respectively.
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serve at Day 10 following treatment with belinostat. Despite
the increase in TK1 gene expression no increase in [18F]
FLT uptake was observed at Day 10. The connection
between TK1 gene expression and TK1 protein expression
was not analyzed in this study so further analysis are
needed in order to elucidate whether the observed increase
in gene expression actually translate into increased protein
expression and activity and how it correlates with [18F]FLT
uptake. That belinostat prevented increase in [18F]FLT
uptake in human ovary cancer xenografts is in line
with one study were the [18F]FLT uptake was analyzed
following treatment with belinostat in a mouse model
of human colon cancer [48]. Effective treatment with
belinostat prevented increase in [18F]FLT uptake in
the colon cancer model.
Even though we did not find a decrease in [18F]FLT
uptake in the belinostat group, within the treatment
group [18F]FLT SUVmean at Day 3 and 6 was correlated
with tumor growth at Day 10. The tumors having the
lowest uptake of [18F]FLT at Day 3 and 6 following initi-
ation of treatment with belinostat were those in which
the treatment was most effective.
Previously we have observed that [18F]FLT uptake was
reduced after initiation of effective anti-cancer therapy
in the A2780 tumor model [41,49]. Thus, thymidine re-
quirement in the A2780 tumor model is most likely
dependent on the salvage pathway. Other studies have
also observed changes in [18F]FLT uptake after initiation
of effective anti-cancer therapies in other models of
human ovarian cancer. In a pre-clinical study [18F]FLT
uptake was decreased following effective mTOR
inhibition with everolimus in a pre-clinical cisplatin-
resistant ovarian tumor model [50]. In cisplatin-sensitive
ovarian cancer xenografts both [18F]FLT and [18F]FDG
uptake were decreased day 4 after initiation of treatment
with cisplatin [51].
Compared to the [18F]FLT data, we observed a higher
influence on [18F]FDG uptake following treatment with
belinostat. At Day 10 uptake of [18F]FDG was decreased
in the treatment group compared to the control group.
The difference at day 10 did only reach significant differ-
ence for SUVmean and not for SUVmax. SUVmean is
the mean tracer concentration in tumor and SUVmax is
a measure of the pixel within the tumor which has the
highest tracer concentration. An explanation to the non-
significant change in SUVmax despite changes in
SUVmean could therefore be because the anti-cancer
treatment is less effective and does not inhibit glucose
uptake in the most aggressive parts of the tumor and
therefore no significant difference between SUVmax for
the treatment and control group was observed. Another
explanation to the differences could be that the differ-
ence for SUVmax did not reach statistical significancedue to a type II error because of the limited amount of
animals included in the study.
The difference in [18F]FDG uptake between the treat-
ment and control group was supported by underlying
changes in gene expression of GLUT1. At Day 10 GLUT1
expressions were lower in the treatment compared to
the control group. Other HDAC inhibitors likewise de-
crease GLUT1 gene expression [52]. Glucose transporters
accounts for [18F]FDG transport into cancer cells and
GLUT1 expression has in many studies been positively
correlated with [18F]FDG uptake [53,54].
Within the treatment group the level of [18F]FDG
uptake at Day 3 and 6 was correlated with treatment
effect at the end of the study. The tumors which had the
lowest [18F]FDG uptake at Day 3 and 6 following treat-
ment start were the tumors which responded best to the
treatment. Projecting this into a clinical situation will
allow identification of the patients responding best to
the treatment. Advantage of this information can be
taken in two ways. Firstly, selection of which patients to
be included in a clinical trial can be determined depending
on drug sensitivity determined early in the treatment
course. This will make identification of new compounds
which are effective in only a small subset of patients eas-
ier. Secondly, in clinical practice, treatment modifications
in non-responding patients during a treatment course
may be undertaken.
Some of the main limitations of the present study were
the lack of protein expression levels of molecular
markers in tumor tissue. It is therefore unknown
whether or not the gene expression levels of Ki67, TK1
and GLUT1 reflected the protein levels of the matching
proteins. However, in other studies a positive correlation
between Ki67 protein and gene expression has been
observed [55,56]. Furthermore does the present study
not describe whether the early changes in tracer uptake
will be predictive for long-term growth inhibition of the
pre-clinical ovary cancer model and if the data acquired
in this pre-clinical mouse model can be translated to
clinical studies.
No regression in tumor volume was observed following
treatment with belinostat; however, the tumor growth was
lower in the treatment compared to the control group,
thus confirming the anti-cancer effect of belinostat. It is
known, that the belinostat compound exerts tumor stasis
rather than tumor shrinkage [26-28]. Identification of effect
with drugs exerting tumor stasis can be difficult, as the
conventional anatomical imaging modalities CT and MRI
measure treatment effect by assessing changes in tumor
size. A tumor stasis effect of the anti-cancer treatment can
consequently be missed by these anatomical imaging mod-
ules. Therefore, identification of biological biomarkers is of
great value in treatment regimes involving tumoristatic
compounds [40].
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In conclusion, we found that [18F]FDG uptake early
following treatment initiation with belinostat predicted
tumor sizes at Day 10, suggesting that [18F]FDG PET
may be a biomarker for non-invasive assessment of anti-
tumor activity of belinostat. The results from this study
supports the addition of [18F]FDG PET scans during
clinical trials with belinostat where it may also be used
for selection of subjects that may enter such studies.
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